Document:

Exhibit
10.8

Regen BioPharma Inc.

A
wholly owned subsidiary of Bio-Matrix Scientific Group Inc.

May 18,
2012

 

Wei-Ping
Min, MD, PhD

Professor,
Department of Surgery

University
of Western Ontario

339 Windermere
Road

LHSC-UC,
C9-136

London,
Ontario

N6A 5A5

Canada

 

Dear Dr.
Wei-Ping Min:

 

This letter
is a follow up to our previous discussion about the Scientific Advisory Board for Regen BioPharma Inc. (a wholly owned subsidiary
of Bio-Matrix Scientific Group Inc.).  The function of the Scientific Advisory Board is to review research directions that
Regen BioPharma Inc. may undertake, determining those projects which may lead to future developments / advancements in the field
of stem cell therapy.  Other areas may be pursued as well, with advice from this advisory board.

 

You will
receive 200,000 shares of Bio-Matrix Common stock as consideration for participating in telephonic calls / conference calls and
serving on Regen BioPharma Inc.’s Scientific Advisory Board.  The frequency and timing of such calls will be established
on a mutually agreeable basis.

 

It is anticipated
that members of the Scientific Advisory Board will potentially serve as primary research consultants to the Company as such projects
are undertaken.  Compensation for such projects will be either at a rate of $500 per hour or negotiated separately on a case-by-case
basis between the Company and the researcher.

 

Thank you
for your consideration,

 

/s/ David
R. Koos                   

Chairman
& CEO

 

P.S.: Please
sign the bottom of this letter in your acceptance and fax back to me at 619.330.2328.  Also, please email me a copy of your
curriculum vitae in word format.  Any usage of your name in any press releases will be submitted to you for review and comment
before being released to the public.

 

 

/s/Wei
Ping Min                      

Wei-Ping
Min, MD, PhD

(date: May
26, 2012)Exhibit
10.9

Exclusive
Option to Negotiate an Exclusive License

Between

Oregon
Health & Science University

and

Regen
BioPharma, Inc.

 

This
Exclusive Option to Negotiate an Exclusive License (this “Agreement”), dated and effective as of June
5, 2012 (the “Effective Date”), is between the Oregon Health & Science University, having offices
at 0690 SW Bancroft Street, L106TT,  Portland, Oregon 97239 (“OHSU”), and Regen BioPharma,
Inc., having offices at 4700 Spring St # 304, La Mesa, CA 91942 (“Optionee”).  OHSU and Optionee
are herein referred to each as a “Party” and collectively as the “Parties.”

1.

BACKGROUND

1.01

OHSU
has certain inventions and discoveries generally described in OHSU Invention Disclosure #0472 entitled “Method for enhancing
hematopoiesis” (the “Invention”).  

1.02

OHSU
desires the Invention to be utilized for the public benefit to the fullest extent possible.

1.03

Optionee
wishes to obtain from OHSU, and OHSU is willing to grant to Optionee, an exclusive option for an exclusive, worldwide, royalty
bearing license to the Patent Rights and a non-exclusive, worldwide, royalty bearing license to the Know-How described in this
Agreement, subject to the terms and conditions set forth below.

 

2.

DEFINITIONS

2.1

“Change
of Control” means (a) the acquisition, either directly or indirectly, through one or a series of transactions by any
third party of more than fifty one percent (51%) of the assets of Optionee; (b) any merger or consolidation involving Optionee
that either directly or indirectly, through one or a series of transactions by which any third party acquires more than fifty
one percent (51%) of the voting stock of Optionee; or (c) the transfer to any third party of all or substantially all the assets
of Optionee relating to the subject matter of this Agreement

2.2

“Confidential
Information” means all information and materials provided by one Party (“Disclosing Party”) to the
other (“Recipient”) and designated as confidential by Disclosing Party when provided.  The term "Confidential
Information" does not include any information or materials that the Recipient demonstrates (a) is or becomes part of the
public domain through no fault of the Recipient or anyone receiving the Confidential Information from Recipient; (b) was already
known to Recipient prior to disclosure as demonstrated through adequate written records; (c) is disclosed to Recipient by a third
party who has the right to make such disclosure; or (d) through adequate written records to have been developed independently
of knowledge of or access to the Confidential Information. The specific terms and conditions of this Agreement are Confidential
Information, but the existence of the Agreement and Field of Use are not.

    	1

    	 

    

 

2.3

 “Field
of Use” means all therapeutic uses related to treatment of diseases in humans.

2.4

 “Inventors”
means the individuals listed as inventors on any patent application or issued patent included within the Patent Rights.

2.5

 “Know-How”
means information, including Confidential Information, provided by the Inventors at their sole election, as set forth in Appendix
A, and materials transferred to Optionee in amounts determined solely by Inventors.

2.6

 “Licensed
Product” means (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes
or would infringe any of the Optioned Technology but for the exception in 35 U.S.C. §271(e)(1), or similar exception in the
U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used,
is covered by, infringes or would infringe any of the Optioned Technology but for the exception in 35 U.S.C. §271(e)(1),
or similar exception in the U.S. or foreign jurisdictions.

2.7

 “Optioned
Technology” means (a) a pending or issued claim of the Patent Rights; and/or (b) the Know-How.

2.8

 “Patent
Costs” means all out of pocket costs incurred by OHSU in connection with the preparation, filing, prosecution, defense,
including interference and opposition proceedings, and maintenance of the Patent Rights.  

2.9

 “Patent
Rights” means the patents and patent applications listed on Appendix A to this Agreement, PCT, U.S. and foreign applications
thereon, including continuations, continuations-in-part (but only to the extent of subject matter therein that is described sufficiently
in the patents and patent applications listed on Appendix A to satisfy the requirements of 35 U.S.C. §112) and divisionals,
patents issuing from any of the foregoing, and reissues, extensions, supplementary protection certificates, substitute applications,
and reexaminations of any of the foregoing.

2.10

 “Term”
means the period beginning on the Effective Date and terminating on the day which is six (6) months after the Effective Date.
This Term is extendable by mutual written agreement of the Parties.

 

3.

GRANT
OF RIGHTS

3.1

Option.

3.1.1

Subject
to the terms and conditions of this Agreement and Optionee’s compliance therewith, OHSU grants to Optionee an exclusive
option during the Term to evaluate the technology and execute an exclusive, worldwide, royalty bearing license in the Field of
Use under the Patent Rights and a non-exclusive, royalty bearing license in the Field of Use to use the Know-How to make, have
made, offer to sell, sell and import Licensed Products for the Field of Use substantially similar to the form of which is attached
hereto as Appendix B.  

3.1.2

Optionee
shall diligently evaluate the Optioned Technology and may exercise this option at any time during the Term by notifying
OHSU in writing of its intent to exercise this option.

3.1.3

OHSU
and Optionee shall negotiate in good faith towards the execution of an exclusive license agreement  with the terms and conditions
substantially similar to those described in Appendix B.  

    	2

    	 

    

 

3.2

Retained
Rights.

3.2.1

OHSU
reserves the right to (i) practice and have practiced the Optioned Technology for research, education and/or non-profit patient
care purposes and publishing any scientific findings or other information relating to or including the Optioned Technology; and
(ii) all right, title and interest in and to the Optioned Technology not expressly granted in Section 3.1.

3.2.2

This
Agreement does not confer any right, title or interest, including any license or rights by implication, estoppel or otherwise,
in tangible or intangible property rights, including any patents, know-how or other inventions or discoveries, that are not explicitly
granted to Optionee in Section 3.1, and OHSU expressly retains those rights.

 

4.

PAYMENTS

 

As
partial consideration for the rights granted to Optionee under this Agreement, Optionee will pay OHSU the following:

4.1

Option
Issue Payment.  Optionee will pay OHSU an option issue payment of Five Thousand U.S. Dollars (US$5,000) within 30 days
after the Effective Date. The aforesaid payment shall be credited towards satisfaction of the upfront license issue payment payable
provided Optionee exercises the option granted herein and executes a license agreement within the Term.  This
Agreement may be extended by mutual agreement for an additional six (6) months for an additional option issue payment of Ten Thousand
U.S. Dollars (US$10,000). The option issue payment(s) may be credited towards the exclusive license upfront payment.

4.2

Reimbursement
of Patent Costs.  Optionee will reimburse OHSU for all Patent Costs occurring during the Term..    

4.3

Payment
Terms.  

4.3.1

Except
as expressly provided in Section 4.1, all payments are nonrefundable and noncreditable, and due and payable to OHSU by Optionee
on the date specified in this Agreement.  In the event no date is specified, payment is due within 30 days from the date
of invoice.  

4.3.2

Any
unpaid invoices or payments will incur a late fee of 1.0% per month (12% per annum) until paid.  Acceptance of late payments
does not negate or waive OHSU's right to seek any other remedy in law, equity or otherwise.

4.3.3

All
amounts payable to OHSU under this Agreement are payable in United States dollars.

4.3.4

All
amounts payable to OHSU under this Agreement are net of all taxes and other charges, and Optionee will be responsible for paying
all taxes, fees and other charges levied by any taxing authority on account of any sums payable under this Agreement.  Optionee
will deliver copies of all official tax receipts.

4.3.5

All
payments required under this Agreement will be delivered by hand, by overnight courier, or by first class, registered or certified
mail, properly addressed to OHSU at the address listed in Section 7.1 below.

    	3

    	 

    

 

5.

CONFIDENTIAL
INFORMATION

5.1

If
Optionee provides Confidential Information to the Fleming Laboratory at OHSU, it must do so through Dr. W. H. Fleming as well
as the authorized representative of OHSU designated in Section 7.1.  Recipient of Confidential Information will protect and
keep that Confidential Information secret and will not (a) disclose that Confidential Information to any person other than to
Recipient's employees, agents and independent contractors with a need to know the Confidential Information to exercise its rights
and/or perform its obligations hereunder, and who have agreed to an obligation of confidentiality and prohibition on use at least
as protective of the Confidential Information as this Section 5; or (b) use that Confidential Information for any purpose other
than to exercise its rights and perform its obligations under this Agreement. Recipient's obligations under Section 5 expire five
years following the later of the expiration or termination of this Agreement.

5.2

If
Recipient is required by law, including Oregon Public Records Law, regulation or court order to disclose any of the Confidential
Information, it will: (a) promptly notify the Disclosing Party; (b) reasonably assist the Disclosing Party to obtain a protective
order or other remedy of Disclosing Party's election; (c) provide Disclosing Party prior review of any disclosure; (d) only provide
that portion of the Confidential Information that is legally required; and (e) make reasonable efforts to obtain reliable assurance
that the Confidential Information will be maintained in confidence.

5.3

Given
the nature of the Confidential Information and the damage that would result to the Disclosing Party upon unauthorized disclosure,
use or transfer of their Confidential Information to any third party, the Parties agree that monetary damages would not be a sufficient
remedy for any breach or threatened breach of this Section 5.  In addition to all other remedies, Disclosing Party will be
entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach
of this Section 5. The breaching Party agrees to waive any requirement for the securing or posting of any bond or the showing
of actual monetary damages in connection with such remedy hereunder.  

 

6.

TERMINATION

6.1

Optionee
may terminate this Agreement for any reason by giving thirty (30) days advance written notice to OHSU and paying OHSU all sums
then due and payable.

6.2

If
Optionee breaches this Agreement or defaults on its payment obligations, OHSU may terminate this Agreement by giving
thirty (30) days advance written notice to Optionee specifying the breach or default under this Agreement, unless
before the end of the 30-day period Optionee has cured the breach or default to the satisfaction of OHSU.

 

7.

GENERAL
PROVISIONS

7.1

Notices.
 All notices or other communications given hereunder shall be in writing, shall be signed by an officer of the Party
sending such notice or other communication, and shall be delivered by hand, by overnight courier, by electronic mail or by facsimile
with all delivery charges prepaid and addressed to the Parties as follows:

    	4

    	 

    

If
to OHSU:

Attention:
 Director

Technology
Transfer & Business Development

Oregon
Health & Science University

0690
SW Bancroft Street, L10TT

Portland,
OR 97239

Phone:
503-494-8200

Fax:
503-494-4729

 

 

If
to Optionee:

 

J.
Christopher Mizer

President

Regen
BioPharma, Inc.

4700
Spring St # 304

 La
Mesa, CA 91942

Phone:
619-702-1404

 

All
notices and communications will be effective on the delivered date if in person, or on the date of the postmark of that notice
or communication if by courier, and on the date of the date stamp of that notice or communication if by electronic mail or facsimile.
 Either Party may change its address by giving notice of that change to the other Party.

7.2

Waivers.
 Neither Party will be deemed to have waived any of its rights under this Agreement until it has signed a written waiver
of those rights.  Without limiting the preceding, no failure or delay by either Party in exercising any rights, powers or
remedies under this Agreement will operate as a waiver of any such right, power or remedy, and no waiver will constitute a waiver
of any other provision, breach, right or remedy, nor will any waiver constitute a continuing waiver or be effective except for
the specific instance and for the specific purpose given.

7.3

Amendments.
 If either Party wishes to modify this Agreement, the Parties will confer in good faith to determine the desirability
of such modification.  No modification will be effective until a written amendment is signed by both Parties.

7.4

Assignment.
 Optionee will not assign or transfer its interests in nor delegate its obligations under this Agreement, whether by
transfer, merger, operation of law or otherwise without OHSU's written consent, which will not be unreasonably withheld.  A
Change of Control of Optionee (voting or otherwise) will be deemed an assignment for purposes of this Section 7.4. An assignment
among entities under common control of Optionee shall not be deemed a Change in Control.  This Agreement will be binding
on and inure to a Party's successors and assigns.  OHSU has the right to assign its Optioned Technology and this

    	5

    	 

    

Agreement
to any successor or assign.

7.5

Governing
Law; Jurisdiction and Venue.  This Agreement will be governed by and construed in accordance with the laws of the State
of Oregon without reference to any choice of law provisions, the Uniform Commercial Code or the International Convention on the
Sale of Goods.  Subject to Section 7.7, any claim, action or suit between OHSU and Optionee that arise out of or relate to
this Agreement and that is not barred by sovereign immunity will be brought and conducted solely and exclusively within the Circuit
Court for Multnomah County, Oregon, provided however, if any such claim, action or suit may be brought only in a federal forum
or pertains to the enforcement of the Patent Rights, and does not waive sovereign immunity on behalf of OHSU unless OHSU so elects
at that time, such claim, action or suit will be brought and conducted solely and exclusively within the United States District
Court of Oregon and Optionee consents to the jurisdiction of and venue in those courts.  Nothing herein will be construed
as a waiver of sovereign immunity.

7.6

Severability.
 The terms and conditions of this Agreement are severable.  If any term or condition of this Agreement is rendered
invalid or unenforceable by any law or regulation, or declared null and void by any court of competent jurisdiction, that part
will be reformed, if possible, to conform to law, and if reformation is not possible, that part will be deleted in such jurisdiction
only and the remainder of the terms and conditions of this Agreement as well as the invalid or unenforceable term or condition
in all jurisdictions where valid and enforceable will remain in full force and effect, unless enforcement of this Agreement without
the invalid or unenforceable term or condition would be grossly inequitable under the circumstances or would frustrate the primary
purpose of this Agreement.

7.7

Dispute
Resolution.  The Parties agree to first attempt to settle amicably any controversy or claim arising out of or relating
to this Agreement by providing copies of documents reasonably requested to enable a Party to evaluate its position. If the Parties
are unable to settle amicably any controversy or claim then both Parties agree that all disputes between them arising out of or
relating to this Agreement will be submitted to non-binding mediation unless the Parties mutually agree otherwise in writing.
 Both Parties agree to exercise their best effort in good faith to resolve all disputes in mediation provided, however, nothing
will limit OHSU's remedies or ability to enforce its rights in the Optioned Technology in any jurisdiction or manner.

7.8

Independent
Contractor; No Agency.  Neither Party will be deemed to be the employee, representative, agent, joint venturer or
partner of the other Party for any purpose.  Neither Party has the authority to obligate or bind the other, or to incur any
liability on behalf of the other, nor to direct the employees of the other.

7.9

Interpretation.
 Both Parties have had the opportunity to have this Agreement reviewed by their attorneys.  Therefore, no rule of
construction or interpretation that favors or disfavors either Party will apply to the interpretation of this Agreement.  Instead,
this Agreement will be interpreted according to the fair meaning of its terms.  The captions or headings of this Agreement
are for convenience of reference only.  They will not limit or otherwise affect the meaning or interpretation of any provision
of this Agreement.  The words "includes" and "including" are not limited in any way and mean "includes
or including without limitation."  The word "person" includes individuals, corporations, partnerships, limited
liability companies, co-operatives, associations and other natural and legal persons.  The term "and/or" means
each and all of the persons, words, provisions or items connected by that term; i.e., it has a joint and several meaning. The
word "will" is a synonym for the word "shall".  All attachments to this Agreement are a part of and are
incorporated in this Agreement.

7.10

Counterparts;
Facsimile Delivery.  This Agreement may be executed in one or more counterparts, each of which will be deemed an original
and all of which together will constitute one and the same Agreement.  This Agreement may be delivered by facsimile, and
when so delivered will have the same force and effect as delivery of an original signature.

    	6

    	 

    

 

7.11

Attorneys'
Fees.  In any legal action or proceeding arising out of or related to this Agreement, the Prevailing Party will
be entitled to recover all reasonable attorneys’ fees incurred at trial, on appeal, and on any petition for review, together
with other costs allowed by law.  For purposes of this Agreement, "Prevailing Party" means the Party that
prevails either affirmatively or by means of a successful defense with respect to claims having the greatest value or importance
as reasonably determined by the mediator or court with jurisdiction over the matter, as applicable and after taking into consideration
any settlement offers made by the Parties.

7.12

ENTIRE
AGREEMENT.  With respect to the Optioned Technology, this Agreement, including its Appendices which are incorporated
herein by reference, is the entire agreement between the Parties and supersedes all prior discussions, representations, warranties
and agreements, both written and oral between the Parties.

 

OHSU:
  OREGON HEALTH & SCIENCE UNIVERSITY

 

 

/s/Andrew
O. Watson

June
6, 2012

 

Andrew
O. Watson

Date

 

Interim
Director, Technology Transfer & Business Development

 

 

OPTIONEE:

REGEN
BIOPHARMA, INC.

 

/s/ J. Christopher Mizer

June 6, 2012

     

J.
Christopher Mizer

Date

 

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]